Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ex vivo whole-blood pharmacodynamics biomarker study in rheumatoid arthritis
NL-OMON38292Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of etanercept, infliximab, adalimumab, rituximab, tocilizumab and 2 more in rheumatoid arthritis (RA) (8 arms), sponsored by Vrije University Medical Center. Started Nov 2011; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON38292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38292.